Opioids for Pain: Restricted Indications and Safety

What They Are

Opioids are a class of agonists of opioid receptors — primarily μ (mu), with contributions from κ (kappa) and δ (delta) — present in the central nervous system and in peripheral tissues. They produce potent analgesia in severe acute pain and in cancer pain, but their use requires care proportional to their potential: physical dependence, tolerance, respiratory depression and risk of overdose are inherent to the class.

The literature frequently separates them into weak opioids and strong opioids. Among the weak, tramadol — μ agonist with additional inhibition of serotonin and norepinephrine reuptake, which explains both part of its analgesic effect and its risk of serotonin syndrome in combinations — and codeine, which is a prodrug converted to morphine by CYP2D6 (an enzyme with important genetic variability, generating slow, normal, and ultrarapid metabolizers). Among the strong: morphine, oxycodone, hydromorphone, fentanyl, and methadone. Buprenorphine is a partial μ agonist — it has an analgesic ceiling and less respiratory depression, with use in management of dependence and in selected chronic pain. Nalbuphine is an opioid of mixed mechanism, with restricted use.

A central point: contemporary international guidelines — CDC 2022, IASP 2021, Canadian and European societies — converge in NOT recommending opioids as first-line in chronic non-cancer pain (chronic low-back pain, fibromyalgia, headache, common neuropathic pain). The legitimate place of opioids is severe acute pain for a short period, moderate-to-severe cancer pain, and palliative care — contexts in which the benefit-risk relationship inverts in favor of use.

Mechanism of Action

Opioids act predominantly through μ receptor agonism (with smaller contributions of κ and δ) in two large territories: in the spinal dorsal horn, where they inhibit the transmission of nociceptive stimulus from the periphery to the ascending pathways; and in supraspinal areas (periaqueductal gray matter — PAG, locus coeruleus, thalamus, amygdala), where they modulate the perception of pain and activate the descending serotonergic and noradrenergic inhibitory system.

The result is potent analgesia — greater effect than NSAIDs or acetaminophen in severe pain — accompanied by effects that are a direct consequence of the same receptor activation: euphoria (related to the mesolimbic system and abuse potential), respiratory depression (respiratory centers in the brainstem), miosis, reduction of gastrointestinal motility (universal constipation in prolonged use), nausea, sedation, and urinary retention.

In chronic use, important receptor adaptations occur: tolerance (internalization and desensitization of μ receptors, requiring increasing dose for the same effect) and physical dependence (neuroplasticity that leads to withdrawal syndrome if the drug is stopped abruptly). A paradoxical peculiarity is opioid-induced hyperalgesia: in some patients on chronic use, the medication itself amplifies pain — and the solution is gradual tapering, not escalation. Tramadol has a special profile: weak μ agonist combined with inhibition of serotonin and norepinephrine reuptake, which brings it pharmacologically close to certain antidepressants and motivates the alert for serotonin syndrome when associated with SSRIs, MAOIs, or linezolid.

Scientific Evidence

The evidence on opioids is one of the most studied in pain pharmacotherapy — and, simultaneously, one that has shifted the most over the last decade. The opioid crisis in the United States and the accumulation of long-term studies motivated careful review of the place of these molecules, with international guidelines converging to a much more restrictive position than that practiced in the 2000s.

The systematic review by Chou et al. (Ann Intern Med 2015), which grounded the first CDC guideline, concluded that the evidence of efficacy of opioids in chronic non-cancer pain over periods > 1 year is limited, while the harms (dependence, overdose, hyperalgesia) grow with time of exposure. The CDC 2022 updated the 2016 guideline with 12 key recommendations, emphasizing that opioids should NOT be the first line in chronic pain and that, when initiated, they should have the minimum effective dose, planned duration, and frequent reassessment.

The IASP 2021 published a convergent position statement — opioids are not first-line in chronic non-cancer pain — reinforcing that multimodal management (exercise, cognitive-behavioral therapy, antidepressants in analgesic dose, anticonvulsants in neuropathic pain, medical acupuncture) should precede any consideration of opioid. The review by Busse et al. (CMAJ 2017) in the Canadian context reached similar conclusions, recommending not initiating opioid in chronic non-cancer pain before exhausting alternatives and establishing conservative dose ceilings for when use is unavoidable.

In continental Europe, systematic reviews and positions of German and Austrian societies (summarized by Häuser et al., Schmerz) converge with the North American documents: opioids have a place in severe acute and cancer pain; in chronic non-cancer pain, the balance between limited efficacy and real risks makes the recommendation much more conservative than two decades ago.

Restricted Indications

The legitimate indications of opioids are specific, and the operational principle is to use the lowest effective dose for the shortest possible time, with frequent reassessment and an explicit discontinuation strategy. The decision to prescribe — and especially to maintain — is always medical, individualized, and depends on a firm diagnosis and absence of adequate alternatives.

How They Are Used

The operational principle of rational opioid use is short and clear: start low, go slow, always reassess. Start with a low dose, escalate slowly per response, and reassess every few days at the start — never renew a prescription without a clinical encounter. In acute postoperative or trauma pain, the horizon is days to 1-2 weeks, with programmed tapering; in cancer pain, the horizon is different, but the discipline of reassessment is maintained.

The choice of route depends on context: intravenous in emergency and hospital postoperative (rapid onset, fine titration); oral (immediate or extended release) in most outpatient situations; transdermal (fentanyl) in cancer patients with stable pain and difficulty with oral route. Combination with simple analgesics (acetaminophen, metamizole) and NSAID when not contraindicated — multimodal analgesia — allows reducing the opioid dose needed for adequate pain control, with consequent reduction of adverse effects.

Opioids — by generic name

All opioids are controlled substances in most countries (e.g. DEA schedules in the US; controlled drug schedules in the UK, Canada, Australia) — they require specific prescription requirements and dispensing controls. Codeine in combination with acetaminophen is a common form in the outpatient setting; morphine is the base of cancer care worldwide;tramadol is frequent in acute pain and in outpatient protocols; oxycodone, hydromorphone, fentanyl, and methadone have a place in oncology and palliative care with variable coverage.

ALL opioids are controlled substances — special prescription requirements; dispensing at controlled pharmacies. Codeine (combined with acetaminophen) is more accessible in outpatient practice in many countries. In public health systems and palliative-care programs, morphine is the base in oncology and palliatives; tramadol also has broad coverage; oxycodone, hydromorphone, transdermal fentanyl, and methadone have variable availability by region. Unequal access to oral morphine generates undertreatment of cancer pain globally — one of the paradoxes international organizations work to address.

Dosing, interactions, and special populations

Older adults. Start with ≤ 50% of the standard adult dose; elevated risk of accumulation, confusion, falls, delirium, and respiratory depression. Preference for opioids with short half-life at start of treatment (avoids accumulation); more frequent reassessment. The polypharmacy typical of the older adult amplifies the risk of interaction — check sedatives, antipsychotics, antidepressants, and antihistamines in use.

Renal failure. Morphine has active metabolites (M6G) that accumulate and may precipitate respiratory depression in renal failure — prefer buprenorphine (Temgesic, Restiva, Buprestic), which has a more favorable renal profile. Tramadol requires dose and interval adjustment. Codeine depends on CYP2D6 and on the elimination of the morphine formed — use with caution.

Hepatic failure. Reduce dose of most opioids. Avoid methadone (unpredictable half-life, risk of long QT). Buprenorphine has a hepatic profile relatively favorable at usual doses, but any opioid in advanced hepatopathy requires a specialist.

Pregnant patients. Chronic use during pregnancy may cause neonatal abstinence syndrome (NAS) — a serious picture requiring specialized neonatal care. Acute use in emergency (severe trauma, postoperative) is acceptable with multidisciplinary discussion (obstetrician, anesthesiologist, neonatologist). Avoid self-medication at any phase of pregnancy.

Lactating patients. Codeine is contraindicated during breastfeeding: ultrarapid CYP2D6 metabolizers may generate toxic levels of morphine in milk, with documented risk of respiratory depression and neonatal death. Morphine in low dose and tramadol require caution and follow-up; analgesic alternatives are preferred.

Risks and adverse effects

The risks of opioids are not mere distant possibilities — they are predictable consequences of the mechanism of action, dose-dependent and time-dependent. Recognizing them explicitly is part of the informed consent that any responsible prescription requires, and the basis for mitigation strategies (minimum dose, limited duration, co-prescription of laxative, take-home naloxone in high risk in international guidelines).

Common adverse effects: constipation is universal and does not develop tolerance — preventive prescription of laxative is indicated from the start of prolonged use. Nausea and vomiting are common in the first weeks and frequently develop tolerance. Sedation, pruritus, miosis, urinary retention, sweating, and dry mouth are frequent. In chronic use: hypogonadism (reduction of testosterone in men, menstrual changes in women), modest immunosuppression, and reduction of bone density have been documented.

Naloxone is a μ receptor antagonist and antidote for overdose — reverses respiratory depression in minutes. Available in hospital settings; in international guidelines (US, Canada, UK), there is a growing recommendation of take-home naloxone in high-risk patients (high dose, co-prescription of benzodiazepine, history of overdose).

Limitations and what is still not known

Despite extensive literature, gray zones persist — and popular conceptions about opioids continue to be reconstructed in light of evidence. The most important point to undo is the binary view: not every prescription is a sure path to dependence, nor is every refusal adequate caution.

Evidence Gaps

Long-term efficacy in chronic non-cancer pain. The evidence that opioids maintain effective analgesia beyond 3-6 months in chronic non-cancer pain is weak. Long-duration trials are rare, and those available show modest effect with high dropout curves — frequently from adverse effects. This sustains the position of the current guidelines, but leaves open which subgroup of chronic patients really benefits.

Individual predictors of dependence are imprecise. Prior history of use disorder, psychiatric comorbidity, and high dose are known risk factors, but no clinical score is sufficiently precise to identify with confidence who will develop opioid use disorder. This motivates active monitoring in every patient on prolonged use.

Absence of consensus on maximum dose in palliative versus chronic non-cancer pain. In palliative, the target is pain control; in chronic non-cancer, international guidelines suggest conservative ceilings (CDC 2022 mentions caution thresholds around 50-90 MME/day) — but those numbers are guidance, not absolute rule.

Unequal access globally. Real paradox: undertreatment of cancer pain in many regions (limited access to oral morphine and other options) coexists with inappropriate use in chronic non-cancer pain (prescription without reassessment plan, without detailed informed consent). Both are clinical problems — and require regional approaches, adequate medical training, and specific public policies.

Relationship with medical acupuncture

Medical acupuncture has a particularly relevant role as a strategy for reduction and discontinuation of opioids — a topic explored in depth in the specific article Acupuncture in Opioid Tapering. Moderate-quality evidence supports that acupuncture integrated into postoperative protocols reduces opioid consumption (sparing effect, documented in multiple meta-analyses) and that, in structured tapering programs, it facilitates gradual reduction with better tolerance by the patient.

Acupuncture does not replace opioid in severe acute pain — the response time and analgesic potency are different. The legitimate role is complementary: reducing the dose needed, facilitating tapering, offering an alternative in chronic non-cancer pain (where opioid is not first line), contributing in cancer pain as adjuvant. Integration in a multimodal plan — discussed in acupuncture in multimodal treatment — is the clinically rational way to combine the two approaches.

When to seek medical help

Opioid use requires continuous medical follow-up — it is not territory for adjustments on one's own. Certain signs indicate the need for faster evaluation or reformulation of the therapeutic plan.